Amgen lifts outlook after strong third-quarter performance

Amgen (Nasdaq: AMGN) has reported stronger-than-expected third-quarter results, driven by double-digit gains across several of its key medicines. Revenue rose 12% year over year to $9.6 billion, ahead of analyst forecasts, while diluted GAAP earnings per share grew 14% to $5.93. Adjusted earnings came in at $5.64 a share, up 1% on the prior year.

The US drugmaker said the quarter’s growth reflected broad-based demand, particularly across its cardiovascular, bone health and respiratory portfolios. Executives credited new launches and expanded indications for helping to offset declines in older products. The company also raised its full-year outlook as sales momentum continued into the final quarter of 2025.

Revenue expansion was led by Repatha (evolocumab), which posted a 40% year-over-year increase to $794 million. The cholesterol-lowering therapy benefited from growing physician confidence and increased patient access, particularly following Amgen’s move to offer it directly to consumers at a reduced monthly price. Sales of Tezspire (tezepelumab-ekko) climbed 40% to $377 million, supported by recent US approval for chronic rhinosinusitis with nasal polyps. Bone health drugs Prolia (denosumab) and Evenity (romosozumab-aqqg) both continued steady growth, with Prolia surpassing $1.1 billion in revenue for the quarter.